Skip to main content

The Impact of Minimal Residual Disease in Acute Lymphoblastic Leukemia

June 16, 2017

[Click here to enlarge.] 


Click Here


Topics Covered

We invite you to learn more about:

  • ​Current treatment options for patients living with ALL
  • The impact of minimal residual disease (MRD)
  • Clinical trials and emerging therapies for ALL treatment
  • The importance of open communication with your healthcare team to promote a better quality of life



Daniel J. DeAngelo, M.D., Ph.D.
Adult Leukemia Program
Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Program Support

Support for this program provided by 


For any questions or comments about this program, please email

< Back to Webcasts